Chemomab Therapeutics Ltd. (id:6392 CMMB)
1.65 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 6:31:35 PM)
Exchange closed, opens in 1 day 14 hours
3.12 USD (3.12%)
-4.07 USD (-4.07%)
18.71 USD (18.71%)
87.50 USD (87.50%)
199.46 USD (199.46%)
-92.61 USD (-92.61%)
-99.10 USD (-99.10%)
About Chemomab Therapeutics Ltd.
Market Capitalization 31.11M
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
| Headquarters (address) |
Building 7 Tel Aviv 6158002 Israel |
| Phone | 972 77 331 0156 |
| Website | https://www.chemomab.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CMMB |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.420 - 2.55 |
| Market Capitalization | 31.11M |
| P/E trailing | -0.801 |
| P/E forward | -41.25 |
| Price/Book | 2.37 |
| Beta | 0.303 |
| EPS | -1.06 |
| EPS Israel (ID:92, base:52) | -0.441 |